These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31190920)

  • 21. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
    Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
    J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
    Strasfeld L; Weinstock DM
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complications of hematopoietic stem transplantation: Fungal infections.
    Omrani AS; Almaghrabi RS
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):239-244. PubMed ID: 28636889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
    Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
    Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.
    Robenshtok E; Gafter-Gvili A; Goldberg E; Weinberger M; Yeshurun M; Leibovici L; Paul M
    J Clin Oncol; 2007 Dec; 25(34):5471-89. PubMed ID: 17909198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D; Depestel DD; Carver PL
    Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of primary antifungal prophylaxis in patients with haematological malignancies.
    Pagano L; Caira M
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients.
    Leonart LP; Tonin FS; Ferreira VL; Penteado STS; Wiens A; Motta FA; Pontarolo R
    J Clin Pharm Ther; 2017 Oct; 42(5):530-538. PubMed ID: 28620958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
    Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
    Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Efficacy and Safety of Antifungal Agents in the Prophylaxis of Oropharyngeal Candidiasis among HIV-Infected Adults: A Systematic Review and Network Meta-Analysis.
    Rajadurai SG; Maharajan MK; Veettil SK; Gopinath D
    Life (Basel); 2022 Mar; 12(4):. PubMed ID: 35455006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
    Ping B; Zhu Y; Gao Y; Yue C; Wu B
    Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of invasive candidal infections: systematic review and meta-analysis.
    Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
    Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cross-sectional investigation of first-choice of antifungal agents in empirical and preemptive antifungal therapy for patients with hematological malignancies].
    Ji Y; Xu LP; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):473-7. PubMed ID: 23827099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
    Marks DI; Liu Q; Slavin M
    Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
    Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.